2023-507516-12-00招募中2 期
A Phase 2 Study of Futibatinib in Combination with PD-1 Antibody-based Standard of Care Therapy in Patients with Solid Tumors
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 15
- 试验地点
- 6
- 主要终点
- Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by investigator assessment
研究概览
简要总结
To evaluate the antitumor efficacy of futibatinib in combination with PD-1 antibody and standard of care chemospherapy.
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Provide written informed consent prior to any study-specific procedures and are willing to comply with all study procedures
- •Have adequate organ function as exemplified in the protocol
- •Able to take medications orally
- •Cohort B only: Has archival tumor tissue available for submission to the central laboratory.
- •Women of child-bearing potential (WOCBP) must have a negative pregnancy test. Female patients are not considered to be of child-bearing potential if they are permanently sterile (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or are post-menopausal (no menses for 12 months without an alternative medical cause)
- •Willing and able to comply with scheduled visits and study procedures
- •Is ≥18 years of age at the time of informed consent (or meets the country’s regulatory definition for legal adult age)
- •Histologically or cytologically confirmed, locally advanced, unresectable or metastatic carcinoma: a. Cohort A: Adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the esophagogastric junction (EGJ). b. Cohort B: Pancreatic ductal adenocarcinoma.
- •No prior systemic treatment for locally advanced, unresectable or metastatic EC (esophageal carcinoma) or PDAC (pancreatic ductal adenocarcinoma).
- •Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1, 2009). A lesion(s) situated in a previously irradiated area can be considered a target lesion(s) if progression has been demonstrated and the lesion(s) is considered measurable per RECIST 1.1 criteria
- •ave documentation of PD-L1 CPS score (Cohort A only).
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
排除标准
- •Has locally advanced esophageal carcinoma or pancreatic cancer that is resectable or potentially curable with radiation therapy (as determined by local investigator)
- •Has known hypersensitivity or severe reaction to any of the study drugs or their excipients, including severe reaction to fluoropyrimidine therapy.
- •Has received prior treatment with an anti-PD-1/PD-L1 or FGF/FGFR targeting drug, or any other agent directed to stimulatory or co-stimulatory T-cell receptor
- •Has known additional malignancy that is progressing or requires active treatment, with the exception of patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or antitumor assessment of the investigational regimen. Exceptions must be discussed with the Sponsor prior to patient enrollment
- •Has had treatment as defined in the protocol within the specified time frame prior to the first dose of study treatment
- •Has a serious illness or medical condition(s)
- •Has a history or current evidence of calcium and phosphate homeostasis disorder or systemic mineral imbalance with ectopic calcification of soft tissues (except commonly observed calcifications in soft tissues such as the skin, kidney, tendons, or vessels due to injury, disease, and aging in the absence of systemic mineral imbalance)
- •Has current evidence of clinically significant retinal disorder as confirmed by ophthalmological examination
- •Is pregnant or lactating female
- •Have a complete absence of dihydropyrimidine dehydrogenase (DPD) activity (blood uracil level ≥150ng/ml).
- •Has some safety specific values defined in the protocol for patients selected to receive oxaliplatin.
- •Has an esophageal carcinoma or pancreatic cancer that is known to be eligible to receive approved targeted therapy (eg, HER-2 positive patients dMMR/MSI-high, germline BRCAmt).
- •Has some specific symptoms defined in the protocol for patients selected to receive cisplatin
- •Patients who have a persistent Grade ≥2 toxicity related to prior treatment.
- •Exclusion only applicable for France
- •Exclusion only applicable for Germany
- •Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in doses exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug
- •Has known human immunodeficiency virus (HIV) and/or history of Hepatitis B or C infections, or known to be positive for Hepatitis B antigen (HBsAg)/ Hepatitis B virus (HBV) DNA or Hepatitis C antibody or RNA. Active Hepatitis C virus (HCV) is defined by a known positive Hepatitis C antibody result and known quantitative HCV RNA results greater than the lower limits of detection of the assay
- •Has an active autoimmune disease that has required systemic treatment in the past 2 years (that is, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (for example, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed
- •Has a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis
- •Has had an allogenic tissue/organ transplant
- •Is unable to swallow tablets/capsules or has any disease or condition that may significantly affect gastrointestinal absorption of futibatinib (eg, inflammatory bowel disease, malabsorption syndrome, or prior gastric/bowel resection)
- •Is judged by the investigator to be ineligible as a participant of the clinical study
结局指标
主要结局
Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by investigator assessment
Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by investigator assessment
次要结局
- Safety based on AEs, SAEs, dose modifications, clinical laboratory parameters, vital signs, electrocardiograms (ECGs), and ophthalmological exams
- Duration of response (DoR) by investigator assessment
- Disease control rate (DCR) by investigator assessment
- Progression-free survival (PFS) by investigator assessment
- 6-month PFS rate by investigator assessment
研究者
Hamdy Elsayed
Scientific
Taiho Oncology Inc.
研究点 (6)
Loading locations...
相似试验
尚未招募
2 期
FUTUREColorectal cancer2024-517573-24-00Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH33
招募中
3 期
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Rheumatoid Arthritis who are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate (SELECT-COMPARE)Rheumatoid arthritis2022-501017-31-00Abbvie Deutschland GmbH & Co. KG489
尚未招募
2 期
Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast CancerNCT07256964Henan Cancer Hospital216
尚未招募
2 期
A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström MacroglobulinemiaNCT07259122Institute of Hematology & Blood Diseases Hospital, China43
尚未招募
3 期
PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal CancerNCT07277842Sun Yat-sen University382